Arrowhead Pharmaceuticals, Inc.
ARWR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000879407
In the last 90 days, Arrowhead Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 2 sales; 501 institutions reported holding it in 13F filings for Q2 2026, worth $9.73B in total; no superinvestor holds it.
13F holders, Q3 2021
Institutional positions in Arrowhead Pharmaceuticals, Inc. as of Sep 30, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 297
- −12 vs. Q2 2021
- Shares held
- 66.6M
- +3.02M (+4.7%) vs. Q2 2021
- Total value
- $4.16B
- −$1.11B (−21.0%) vs. Q2 2021
- New holders
- 37
- 109 more added
- Sold out
- 49
- 103 more reduced
5 institutions that held it in Q2 2021 haven't filed for Q3 2021 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ARWR on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 501 | $9.73B |
| Q1 2026 | 437 | $7.58B |
| Q4 2025 | 401 | $7.70B |
| Q3 2025 | 303 | $3.83B |
| Q2 2025 | 281 | $1.67B |
| Q1 2025 | 264 | $1.34B |
| Q4 2024 | 269 | $1.88B |
| Q3 2024 | 272 | $1.90B |
| Q2 2024 | 272 | $2.54B |
| Q1 2024 | 273 | $2.76B |
| Q4 2023 | 266 | $2.37B |
| Q3 2023 | 257 | $2.01B |
| Q2 2023 | 274 | $2.57B |
| Q1 2023 | 257 | $1.85B |
| Q4 2022 | 282 | $2.97B |
| Q3 2022 | 278 | $2.35B |
| Q2 2022 | 279 | $2.54B |
| Q1 2022 | 307 | $3.19B |
| Q4 2021 | 311 | $4.51B |
| Q3 2021 | 297 | $4.16B |
| Q2 2021 | 314 | $5.54B |
| Q1 2021 | 289 | $4.55B |
Institutions, Q3 2021
Shares, value and share of portfolio for each institution holding Arrowhead Pharmaceuticals, Inc.; share changes are against Q2 2021.